Stock Track | CHINARES PHARMA Soars 5.17% Intraday on Strong FY2025 Results That Beat Estimates

Stock Track03-25

CHINARES PHARMA's stock surged 5.17% during intraday trading on Wednesday, following the release of its full-year 2025 financial results.

The pharmaceutical company reported profit attributable to shareholders of RMB4.05 billion, representing a significant 20.7% increase compared to the previous year. Revenue for the period reached RMB269.57 billion, marking a 4.6% year-on-year growth.

Both earnings per share of RMB0.64 and total revenue exceeded analyst expectations, with the pharmaceutical manufacturing segment showing particularly strong performance with a 10.2% revenue increase and improved gross margins. The board also proposed a final dividend of RMB0.122 per share, contributing to positive investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108123042?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108123042","market":"hk","top_or_hot":-1,"title":"Stock Track | CHINARES PHARMA Soars 5.17% Intraday on Strong FY2025 Results That Beat Estimates","media":"Stock Track","content":"<p>CHINARES PHARMA's stock surged 5.17% during intraday trading on Wednesday, following the release of its full-year 2025 financial results.</p><p>The pharmaceutical company reported profit attributable to shareholders of RMB4.05 billion, representing a significant 20.7% increase compared to the previous year. Revenue for the period reached RMB269.57 billion, marking a 4.6% year-on-year growth.</p><p>Both earnings per share of RMB0.64 and total revenue exceeded analyst expectations, with the pharmaceutical manufacturing segment showing particularly strong performance with a 10.2% revenue increase and improved gross margins. The board also proposed a final dividend of RMB0.122 per share, contributing to positive investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CHINARES PHARMA Soars 5.17% Intraday on Strong FY2025 Results That Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CHINARES PHARMA Soars 5.17% Intraday on Strong FY2025 Results That Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-25 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA's stock surged 5.17% during intraday trading on Wednesday, following the release of its full-year 2025 financial results.</p><p>The pharmaceutical company reported profit attributable to shareholders of RMB4.05 billion, representing a significant 20.7% increase compared to the previous year. Revenue for the period reached RMB269.57 billion, marking a 4.6% year-on-year growth.</p><p>Both earnings per share of RMB0.64 and total revenue exceeded analyst expectations, with the pharmaceutical manufacturing segment showing particularly strong performance with a 10.2% revenue increase and improved gross margins. The board also proposed a final dividend of RMB0.122 per share, contributing to positive investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1108123042","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108123042","pubTimestamp":1774402347,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CHINARES PHARMA's stock surged 5.17% during intraday trading on Wednesday, following the release of its full-year 2025 financial results.The pharmaceutical company reported profit attributable to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"个股追踪|2025财年业绩强劲超预期CHINARES PHARMA盘中大涨5.17%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"CHINARES PHARMA's stock surged 5.17% during intraday trading on Wednesday, following the release of its full-year 2025 financial results.The pharmaceutical company reported profit attributable to shareholders of RMB4.05 billion, representing a significant 20.7% increase compared to the previous year. Revenue for the period reached RMB269.57 billion, marking a 4.6% year-on-year growth.Both earnings per share of RMB0.64 and total revenue exceeded analyst expectations, with the pharmaceutical manufacturing segment showing particularly strong performance with a 10.2% revenue increase and improved gross margins. The board also proposed a final dividend of RMB0.122 per share, contributing to positive investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108123042","isCrawlerRequest":true}